Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Cognitive tests and assessment

Topic: Amyloid, tau and blood-test diagnosis

We found significant main effects between GFAP groups and age, diagnosis of AD, diagnosis of VaD, MoCA, sex, CRP and BMI. Pairwise comparisons revealed significant differences between all GFAP groups, age, and MoCA scores. Low and medium GFAP levels were related to CRP levels. Low and medium, and low and high GFAP levels were related to BMI. No differences were found between GFAP status and nutrition, sleep, smoking, number of comorbidities, Fazekas scale and diagnosis of MCI or V-MCI. Neuroinflammation (GFAP levels) increases as individuals age, but to a greater extent in the presence of cognitive impairment (especially AD and VaD groups). Levels of peripheral inflammation (CRP) and BMI, were inversely associated with neuroinflammation. Elevated GFAP levels were not related to increased MRI white matter lesions or other elements of vascular disease. Further studies will investigate these complex relationships.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lima, B. S., Rosa‐Neto, P., Lahiri, D., Roncero, C. T., & Chertkow, H. (2025). The relationship between neuroinflammation and clinical features of dementia: An investigation of GFAP levels in Alzheimer's disease and related disorders. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_098224

Vancouver

Lima BS, Rosa‐Neto P, Lahiri D, Roncero CT, Chertkow H. The relationship between neuroinflammation and clinical features of dementia: An investigation of GFAP levels in Alzheimer's disease and related disorders. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_098224. PMID: 41443611.

BibTeX

@article{lima2025-41443611,
  author  = {Lima, Bruna Seixas and Rosa‐Neto, Pedro and Lahiri, Durjoy and Roncero, Carlos Tyler and Chertkow, Howard},
  title   = {{The relationship between neuroinflammation and clinical features of dementia: An investigation of GFAP levels in Alzheimer's disease and related disorders}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_098224},
  pmid    = {41443611},
  url     = {https://doi.org/10.1002/alz70856_098224}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study found that higher GFAP levels, a marker of neuroinflammation, were linked to older age and to diagnoses of Alzheimer's and vascular dementia. It describes relationships between inflammation and clinical features but does not test any treatment.

Study details

How this study scored 38/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 1 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 36 of the 96 points it could be judged on, which is 38 of 100. Total 38 of 100.36 of the 96 points we could judge = 38 of 100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 36 of the 96 points we could judge it on, which is 38 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 60 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Howard Chertkow holds only 6 work(s), too few to judge a track record — left out of this score
Institution's track record 1 / 3 McGill University: institution h-index 1,373 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41443611)
Free to read 2 / 2 Free to read
Points 36 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 36 of the 96 points we could judge it on is 38 out of 100.
Total 38 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Cognitive tests and assessment

Also tagged “cerebrospinal”

822 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 822 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →